Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis

This study is ongoing, but not recruiting participants.
Children's Hospital of Philadelphia
University of Iowa
Information provided by (Responsible Party):
Spark Therapeutics, LLC Identifier:
First received: October 21, 2009
Last updated: October 31, 2014
Last verified: October 2014

October 21, 2009
October 31, 2014
October 2012
June 2015   (final data collection date for primary outcome measure)
Mobility testing [ Time Frame: One year ] [ Designated as safety issue: No ]
Pupillary light reflex (PLR)- increased sensitivity to light as evidenced by increased velocity of constriction and/or increased amplitude of constriction [ Time Frame: Six months ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00999609 on Archive Site
  • Additional visual/retinal function tests [ Time Frame: One year ] [ Designated as safety issue: No ]
  • Ophthalmic exams, physical exams, immunology studies, clinical labs, & adverse event recording [ Time Frame: Two years ] [ Designated as safety issue: Yes ]
  • Additional visual/retinal function tests and ocular motility measurements [ Time Frame: Six months ] [ Designated as safety issue: No ]
  • Ophthalmic exams, physical exams, immunology studies, clinical labs, & adverse event recording [ Time Frame: Six months ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis
A Safety and Efficacy Study in Subjects With Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE) [AAV2-hRPE65v2-301]

The study is a Phase 3, open-label, randomized controlled trial of gene therapy intervention by subretinal administration of AAV2-hRPE65v2. At least twenty-four subjects, three years of age or older, will be recruited. The intervention group will receive AAV2-hRPE65v2 vector at either The Children's Hospital of Philadelphia or University of Iowa to determine if it improves visual and retinal function in individuals with LCA2.

Leber congenital amaurosis (LCA) is a disease where part of the eye (the retina) is severely diseased. Usually it is detected in affected people within the first few months of life, as there is significantly poor vision at birth. Cells in the retina are lost over time in people with LCA which leads to total blindness. There are no pharmacological treatments available. This study will focus on the form of LCA caused by changes (mutations) in DNA that makes a certain protein (called the 65 kDa retinal pigment epithelium (RPE)-specific protein, or RPE65). Clinical diagnosis is made by function tests of the eye. This can be confirmed by a special method of testing (molecular testing) to verify that the RPE65 is not correct.

This study uses a gene therapy vector made from an adeno-associated virus (AAV) called AAV2-hRPE65v2. Gene therapy refers to the incorporation of new DNA into cells with the goal of supplying a therapeutic gene or a gene that is missing or not functioning in the cell. The AAV parts of the gene therapy vector work as a delivery vehicle for getting the normal human RPE65 gene into the cells of the retina. An earlier clinical study of AAV2-hRPE65v2 was conducted based on the demonstration of safety and effectiveness of the vector in animals with a similar eye disease. The earlier clinical study tested three doses of the vector in twelve children and adults. The three doses were safe for the eye and the rest of the body in individuals as young as eight years old. AAV2-hRPE65v2 administration also led to increased vision in the subjects, with the youngest subjects showing the most improvement.

This study will deliver AAV2-hRPE65v2 vector to at least sixteen intervention group subjects, age three or older; subjects will receive the vector in both eyes via subretinal injections during surgeries (on separate days). The purpose of this research study is to assess the effectiveness and safety of the AAV2-hRPE65v2 gene therapy vector as a possible treatment for LCA2. The control group of at least eight subjects will be able to cross-over to the intervention group after one year, provided they still meet all eligibility criteria.

Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Inherited Retinal Dystrophy Due to RPE65 Mutations
Biological: AAV2-hRPE65v2
Subretinal administration of gene therapy vector AAV2-hRPE65v2 (1.5E11 vector genomes per eye) to both eyes via surgical procedures on separate days.
Other Names:
  • AAV2-hRPE65v2
  • gene therapy vector
  • Experimental: AAV2-hRPE65v2
    Intervention: Biological: AAV2-hRPE65v2
  • No Intervention: Control

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
April 2029
June 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Willingness to adhere to protocol and long-term follow-up as evidenced by written informed consent or parental permission and subject assent (where applicable).
  • Diagnosis of LCA due to RPE65 mutations; molecular diagnosis is to be performed, or confirmed, by a CLIA-approved laboratory.
  • Age three years old or older.
  • Visual acuity worse than 20/60 (both eyes) and/or visual field less than 20 degrees in any meridian as measured by a III4e isopter or equivalent (both eyes).
  • Sufficient viable retinal cells as determined by non-invasive means, such as optical coherence tomography (OCT) and/or ophthalmoscopy. Must have either: 1) an area of retina within the posterior pole of >100 µm thickness shown on OCT; 2) ≥ 3 disc areas of retina without atrophy or pigmentary degeneration within the posterior pole; or 3) remaining visual field within 30 degrees of fixation as measured by a III4e isopter or equivalent.
  • Subjects must be evaluable on mobility testing (the primary efficacy endpoint) to be eligible for the study. Evaluable is defined as: 1) The ability to perform mobility testing within the luminance range evaluated in the study. Individuals must receive an accuracy score of ≤ 1 during screening mobility testing at 400 lux or less to be eligible; individuals with an accuracy score of > 1 on all screening mobility test runs at 400 lux, or those who refuse to perform mobility testing at screening, will be excluded. (See Appendix 3 for a description of accuracy score.); 2) The inability to pass mobility testing at 1 lux. Individuals must fail screening mobility testing at 1 lux to be eligible; individuals that pass one or more screening mobility test runs at 1 lux will be excluded.

Exclusion Criteria:

  • Unable or unwilling to meet requirements of the study, including receiving bilateral subretinal vector administrations.
  • Any prior participation in a study in which a gene therapy vector was administered.
  • Participation in a clinical study with an investigational drug in the past six months.
  • Use of retinoid compounds or precursors that could potentially interact with the biochemical activity of the RPE65 enzyme; individuals who discontinue use of these compounds for 18 months may become eligible.
  • Prior intraocular surgery within six months.
  • Known sensitivity to medications planned for use in the peri-operative period.
  • Pre-existing eye conditions or complicating systemic diseases that would preclude the planned surgery or interfere with the interpretation of study. Complicating systemic diseases would include those in which the disease itself, or the treatment for the disease, can alter ocular function. Examples are malignancies whose treatment could affect central nervous system function (for example: radiation treatment of the orbit; leukemia with CNS/optic nerve involvement). Subjects with diabetes or sickle cell disease would be excluded if they had any manifestation of advanced retinopathy (e.g., macular edema or proliferative changes). Also excluded would be subjects with immunodeficiency (acquired or congenital) as there could be susceptibility to opportunistic infection (such as CMV retinitis).
  • Individuals of childbearing potential who are pregnant or unwilling to use effective contraception for four months following vector administration.
  • Individuals incapable of performing mobility testing (the primary efficacy endpoint) for reason other than poor vision, including physical or attentional limitations.
  • Any other condition that would not allow the potential subject to complete follow-up examinations during the course of the study or, in the opinion of the investigator, makes the potential subject unsuitable for the study.
  • Subjects will not be excluded based on their gender, race, or ethnicity.
3 Years and older
Contact information is only displayed when the study is recruiting subjects
United States
Spark Therapeutics, LLC
Spark Therapeutics, LLC
  • Children's Hospital of Philadelphia
  • University of Iowa
Principal Investigator: Albert M Maguire, MD Children's Hospital of Philadelphia
Principal Investigator: Stephen R Russell, MD University of Iowa
Spark Therapeutics, LLC
October 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP